Targeting epigenetic regulatory machinery to overcome cancer therapy resistance

A combination strategy targeting enhancer plasticity exerts synergistic lethality against BETi-resistant leukemia cells

(2020) Lei Guo et al.   Nature Communications

The PROTAC technology in drug development

(2019) Yutian Zou et al.   CELL BIOCHEMISTRY AND FUNCTION

Chromatin accessibility and the regulatory epigenome

(2019) Sandy L. Klemm et al.   NATURE REVIEWS GENETICS

Integrative single-cell analysis

(2019) Tim Stuart et al.   NATURE REVIEWS GENETICS

Targeting epigenetic modifications in cancer therapy: erasing the roadmap to cancer

(2019) Helai P. Mohammad et al.   NATURE MEDICINE

BCL2 Amplicon Loss and Transcriptional Remodeling Drives ABT-199 Resistance in B Cell Lymphoma Models

(2019) Xiaohong Zhao et al.   CANCER CELL

Long-range enhancer–promoter contacts in gene expression control

(2019) Stefan Schoenfelder et al.   NATURE REVIEWS GENETICS

The roles of DNA, RNA and histone methylation in ageing and cancer

(2019) Ewa M. Michalak et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Targeting enhancer switching overcomes non-genetic drug resistance in acute myeloid leukaemia

(2019) Charles C. Bell et al.   Nature Communications

Combining epigenetic drugs with other therapies for solid tumours — past lessons and future promise

(2019) Daphné Morel et al.   Nature Reviews Clinical Oncology

The diverse roles of DNA methylation in mammalian development and disease

(2019) Maxim V. C. Greenberg et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/EGFR mutation double‐positive lung cancer

(2019) Shinji Takeuchi et al.   CANCER SCIENCE

Metabolic regulation of gene expression by histone lactylation

(2019) Di Zhang et al.   NATURE

A view on drug resistance in cancer

(2019) Neil Vasan et al.   NATURE

The great escape: tumour cell plasticity in resistance to targeted therapy

(2019) Soufiane Boumahdi et al.   NATURE REVIEWS DRUG DISCOVERY

Adaptive mutability of colorectal cancers in response to targeted therapies

(2019) Mariangela Russo et al.   SCIENCE

The timeline of epigenetic drug discovery: from reality to dreams

(2019) A. Ganesan et al.   Clinical Epigenetics

Toward Minimal Residual Disease-Directed Therapy in Melanoma

(2018) Florian Rambow et al.   CELL

Hypoxia Promotes Resistance to EGFR Inhibition in NSCLC Cells via the Histone Demethylases, LSD1 and PLU-1

(2018) Yuhong Lu et al.   MOLECULAR CANCER RESEARCH

Highly scalable generation of DNA methylation profiles in single cells

(2018) Ryan M Mulqueen et al.   NATURE BIOTECHNOLOGY

The Key Role of Epigenetics in Human Disease Prevention and Mitigation

(2018) Andrew P. Feinberg   NEW ENGLAND JOURNAL OF MEDICINE

Intratumor heterogeneity in epigenetic patterns

(2018) Yassen Assenov et al.   SEMINARS IN CANCER BIOLOGY

Cancer Stem Cells (CSCs) in Drug Resistance and their Therapeutic Implications in Cancer Treatment

(2018) Lan Thi Hanh Phi et al.   Stem Cells International

Non-Coding RNAs and Resistance to Anticancer Drugs in Gastrointestinal Tumors

(2018) Jens C. Hahne et al.   Frontiers in Oncology

Epigenetic tools (The Writers, The Readers and The Erasers) and their implications in cancer therapy

(2018) Subhankar Biswas et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Profiling DNA Methylation Based on Next-Generation Sequencing Approaches: New Insights and Clinical Applications

(2018) Daniela Barros-Silva et al.   Genes

The Network of Non-coding RNAs in Cancer Drug Resistance

(2018) Fabio Corrà et al.   Frontiers in Oncology

Resistance to Epigenetic-Targeted Therapy Engenders Tumor Cell Vulnerabilities Associated with Enhancer Remodeling

(2018) Amanda Balboni Iniguez et al.   CANCER CELL

KDM5 Histone Demethylase Activity Links Cellular Transcriptomic Heterogeneity to Therapeutic Resistance

(2018) Kunihiko Hinohara et al.   CANCER CELL

A cell identity switch allows residual BCC to survive Hedgehog pathway inhibition

(2018) Brian Biehs et al.   NATURE

p53-dependent autophagic degradation of TET2 modulates cancer therapeutic resistance

(2018) Jixiang Zhang et al.   ONCOGENE

Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance

(2017) Sydney M. Shaffer et al.   NATURE

The evidence framework for precision cancer medicine

(2017) Jeffrey A. Moscow et al.   Nature Reviews Clinical Oncology

Marked for death: targeting epigenetic changes in cancer

(2017) Sophia Xiao Pfister et al.   NATURE REVIEWS DRUG DISCOVERY

The DNA methyltransferase family: a versatile toolkit for epigenetic regulation

(2017) Frank Lyko   NATURE REVIEWS GENETICS

TET-mediated active DNA demethylation: mechanism, function and beyond

(2017) Xiaoji Wu et al.   NATURE REVIEWS GENETICS

Single-cell analysis resolves the cell state transition and signaling dynamics associated with melanoma drug-induced resistance

(2017) Yapeng Su et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The cancer epigenome: Concepts, challenges, and therapeutic opportunities

(2017) Mark A. Dawson   SCIENCE

A New View of Pathway-Driven Drug Resistance in Tumor Proliferation

(2017) Ruth Nussinov et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

DNA methylation at enhancers identifies distinct breast cancer lineages

(2017) Thomas Fleischer et al.   Nature Communications

Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacologic Targeting of the P-TEFb Complex

(2017) Jon S. Zawistowski et al.   Cancer Discovery

DNA Hypomethylating Drugs in Cancer Therapy

(2017) Takahiro Sato et al.   Cold Spring Harbor Perspectives in Medicine

Tumor cell-intrinsic phenotypic plasticity facilitates adaptive cellular reprogramming driving acquired drug resistance

(2017) Heinz Hammerlindl et al.   Journal of Cell Communication and Signaling

Cancer Stem Cells: Basic Concepts and Therapeutic Implications

(2016) Dany Nassar et al.   Annual Review of Pathology-Mechanisms of Disease

Epigenetic Regulation of the Homeobox Gene MSX1 Associates with Platinum-Resistant Disease in High-Grade Serous Epithelial Ovarian Cancer

(2016) N. A. Bonito et al.   CLINICAL CANCER RESEARCH

Enhancer methylation dynamics contribute to cancer plasticity and patient mortality

(2016) Rachel E. Bell et al.   GENOME RESEARCH

Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia

(2016) Stefanie Göllner et al.   NATURE MEDICINE

DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling

(2016) Olga A Guryanova et al.   NATURE MEDICINE

Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition

(2016) Aaron N Hata et al.   NATURE MEDICINE

From profiles to function in epigenomics

(2016) Stefan H. Stricker et al.   NATURE REVIEWS GENETICS

The molecular hallmarks of epigenetic control

(2016) C. David Allis et al.   NATURE REVIEWS GENETICS

Coming of age: ten years of next-generation sequencing technologies

(2016) Sara Goodwin et al.   NATURE REVIEWS GENETICS

Non-coding RNAs as regulators in epigenetics

(2016) Jian-Wei Wei et al.   ONCOLOGY REPORTS

Lateral Thinking: How Histone Modifications Regulate Gene Expression

(2016) Moyra Lawrence et al.   TRENDS IN GENETICS

Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells

(2016) Michael Ramirez et al.   Nature Communications

Resistance to BET Bromodomain Inhibitors Is Mediated by Kinome Reprogramming in Ovarian Cancer

(2016) Alison M. Kurimchak et al.   Cell Reports

Epigenetic polypharmacology: from combination therapy to multitargeted drugs

(2016) Angel R. de Lera et al.   Clinical Epigenetics

Changes in DNA methylation are associated with the development of drug resistance in cervical cancer cells

(2015) Chih-Cheng Chen et al.   Cancer Cell International

Transcriptional plasticity promotes primary and acquired resistance to BET inhibition

(2015) Philipp Rathert et al.   NATURE

BET inhibitor resistance emerges from leukaemia stem cells

(2015) Chun Yew Fong et al.   NATURE

HDAC inhibitors still need a home run, despite recent approval

(2015) Malini Guha   NATURE REVIEWS DRUG DISCOVERY

Erratum: A stress-induced early innate response causes multidrug tolerance in melanoma

(2015) D Ravindran Menon et al.   ONCOGENE

Comparison of 2D- and 3D-culture models as drug-testing platforms in breast cancer

(2015) YOSHINORI IMAMURA et al.   ONCOLOGY REPORTS

DNA methylation of oestrogen-regulated enhancers defines endocrine sensitivity in breast cancer

(2015) Andrew Stone et al.   Nature Communications

Role of DNA Methylation in Modulating Transcription Factor Occupancy

(2015) Matthew T. Maurano et al.   Cell Reports

Polo Like Kinase 2 Tumour Suppressor and cancer biomarker: new perspectives on drug sensitivity/resistance in ovarian cancer

(2015) Helen M. Coley et al.   Oncotarget

Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors

(2014) S Bauer et al.   BRITISH JOURNAL OF CANCER

A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer

(2014) R M Glasspool et al.   BRITISH JOURNAL OF CANCER

Integrated analysis of DNA methylation and mRNA expression profiling reveals candidate genes associated with cisplatin resistance in non-small cell lung cancer

(2014) You-Wei Zhang et al.   Epigenetics

Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression

(2014) Noemi Reguart et al.   LUNG CANCER

p16 Methylation is associated with chemosensitivity to fluorouracil in patients with advanced gastric cancer

(2014) Mingming Wang et al.   MEDICAL ONCOLOGY

An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia

(2014) Birgit Knoechel et al.   NATURE GENETICS

Non-histone protein methylation as a regulator of cellular signalling and function

(2014) Kyle K. Biggar et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

The relationship between DNA methylation, genetic and expression inter-individual variation in untransformed human fibroblasts

(2014) James R Wagner et al.   GENOME BIOLOGY

Drug Resistance in Cancer: An Overview

(2014) Genevieve Housman et al.   Cancers

Overcoming Intrinsic Multidrug Resistance in Melanoma by Blocking the Mitochondrial Respiratory Chain of Slow-Cycling JARID1Bhigh Cells

(2013) Alexander Roesch et al.   CANCER CELL

Colon Cancer Cells Escape 5FU Chemotherapy-Induced Cell Death by Entering Stemness and Quiescence Associated with the c-Yes/YAP Axis

(2013) Y. Touil et al.   CLINICAL CANCER RESEARCH

Non-coding RNAs as direct and indirect modulators of epigenetic regulation

(2013) Veronica J Peschansky et al.   Epigenetics

Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies

(2013) Gerald S. Falchook et al.   INVESTIGATIONAL NEW DRUGS

A phase I/II study of decitabine in combination with panitumumab in patients with wild-type (wt) KRAS metastatic colorectal cancer

(2013) I. Garrido-Laguna et al.   INVESTIGATIONAL NEW DRUGS

Randomized Phase II, Double-Blind, Placebo-Controlled Study of Exemestane With or Without Entinostat in Postmenopausal Women With Locally Recurrent or Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Treatment With a Nonsteroidal Aromatase Inhibitor

(2013) Denise A. Yardley et al.   JOURNAL OF CLINICAL ONCOLOGY

Recurrent high-grade glioma treated with bevacizumab: prognostic value of MGMT methylation, EGFR status and pretreatment MRI in determining response and survival

(2013) Christina Chen et al.   JOURNAL OF NEURO-ONCOLOGY

BCL-2 Hypermethylation Is a Potential Biomarker of Sensitivity to Antimitotic Chemotherapy in Endocrine-Resistant Breast Cancer

(2013) A. Stone et al.   MOLECULAR CANCER THERAPEUTICS

A Phase II Study of Temozolomide in Patients with Advanced Aerodigestive Tract and Colorectal Cancers and Methylation of the O6-Methylguanine-DNA Methyltransferase Promoter

(2013) D. Hochhauser et al.   MOLECULAR CANCER THERAPEUTICS

DNA methylation: roles in mammalian development

(2013) Zachary D. Smith et al.   NATURE REVIEWS GENETICS

TETonic shift: biological roles of TET proteins in DNA demethylation and transcription

(2013) William A. Pastor et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

SULF2 Methylation Is Associated with In Vitro Cisplatin Sensitivity and Clinical Efficacy for Gastric Cancer Patients Treated with a Modified FOLFOX Regimen

(2013) Jie Shen et al.   PLoS One

Epigenetic status of argininosuccinate synthetase and argininosuccinate lyase modulates autophagy and cell death in glioblastoma

(2013) N Syed et al.   Cell Death & Disease

DNA methylation of distal regulatory sites characterizes dysregulation of cancer genes

(2013) Dvir Aran et al.   GENOME BIOLOGY

Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells

(2012) Twee Tsao et al.   ANNALS OF HEMATOLOGY

Targeted Casp8AP2 methylation increases drug resistance in mesenchymal stem cells and cancer cells

(2012) Kuan-Der Lee et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance

(2012) Roel H. Wilting et al.   DRUG RESISTANCE UPDATES

Widespread plasticity in CTCF occupancy linked to DNA methylation

(2012) H. Wang et al.   GENOME RESEARCH

Integrated epigenomics identifiesBMP4as a modulator of cisplatin sensitivity in gastric cancer

(2012) Tatiana Ivanova et al.   GUT

A phase II evaluation of belinostat and carboplatin in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma: A gynecologic oncology group study

(2012) Don S. Dizon et al.   GYNECOLOGIC ONCOLOGY

Phase II Activity of Belinostat (PXD-101), Carboplatin, and Paclitaxel in Women With Previously Treated Ovarian Cancer

(2012) Don S. Dizon et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance

(2012) Justin M Balko et al.   NATURE MEDICINE

DNA Methylation and Its Basic Function

(2012) Lisa D Moore et al.   NEUROPSYCHOPHARMACOLOGY

IGFBP-3 methylation-derived deficiency mediates the resistance to cisplatin through the activation of the IGFIR/Akt pathway in non-small cell lung cancer

(2012) M Cortés-Sempere et al.   ONCOGENE

Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling

(2012) C Zeller et al.   ONCOGENE

Circumventing Cancer Drug Resistance in the Era of Personalized Medicine

(2012) Levi A. Garraway et al.   Cancer Discovery

DOT1L, the H3K79 methyltransferase, is required for MLL-AF9-mediated leukemogenesis

(2011) A. T. Nguyen et al.   BLOOD

A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer

(2011) P N Munster et al.   BRITISH JOURNAL OF CANCER

Polo-like Kinase Plk2 Is an Epigenetic Determinant of Chemosensitivity and Clinical Outcomes in Ovarian Cancer

(2011) N. Syed et al.   CANCER RESEARCH

Regulation of chromatin by histone modifications

(2011) Andrew J Bannister et al.   CELL RESEARCH

MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma

(2011) A. L. Rivera et al.   NEURO-ONCOLOGY

Aberrant DNA methylation of apoptotic signaling genes in patients responsive and nonresponsive to therapy for cervical carcinoma

(2010) Patimaporn Chaopatchayakul et al.   AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY

Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer

(2010) Siqing Fu et al.   CANCER

Identification of Hypermethylated Genes Associated with Cisplatin Resistance in Human Cancers

(2010) Xiaofei Chang et al.   CANCER RESEARCH

A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations

(2010) Sreenath V. Sharma et al.   CELL

A Temporarily Distinct Subpopulation of Slow-Cycling Melanoma Cells Is Required for Continuous Tumor Growth

(2010) Alexander Roesch et al.   CELL

Tumor-initiating cells are not enriched in cisplatin-surviving BRCA1;p53-deficient mammary tumor cells in vivo

(2010) Marina Pajic et al.   CELL CYCLE

Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer

(2010) Daniel P. Silver et al.   JOURNAL OF CLINICAL ONCOLOGY

EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer

(2010) A Singh et al.   ONCOGENE

Methylation of BNIP3 and DAPK indicates lower response to chemotherapy and poor prognosis in gastric cancer

(2010) Sugita   ONCOLOGY REPORTS

Epigenetic silencing of argininosuccinate synthetase confers resistance to platinum-induced cell death but collateral sensitivity to arginine auxotrophy in ovarian cancer

(2009) Linda J. Nicholson et al.   INTERNATIONAL JOURNAL OF CANCER

Promoter hypermethylation in tumour suppressor genes and response to interleukin-2 treatment in bladder cancer: a pilot study

(2009) Sonata Jarmalaite et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Azacitidine favorably modulates PSA kinetics correlating with plasma DNA LINE-1 hypomethylation in men with chemonaïve castration-resistant prostate cancer

(2009) Guru Sonpavde et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Resistance mechanisms to cancer chemotherapy

(2008) Kelly Marie Redmond   Frontiers in Bioscience-Landmark

Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts

(2008) Gaspar J. Kitange et al.   NEURO-ONCOLOGY